TFS Corporate Presentation

It’s all about…

Founded in 1996 with headquarters

in Sweden

Largest privately owned European clinical

CRO

Worldwide ranking no 14*

~ 550 employees

Operations inspected by US FDA, EMA,

MHRA (UK) and MPA (Sweden)

Geographical coverage in Europe,

USA and Japan

Conducting clinical trials in 34 countries

worldwide (December 2012) **

Projected revenue €50 million in 2013

The TFS Group - Facts and Figures

*) Based on the Scrip Clinical Research Report; “SCR 18 league

tables”, net revenue estimations 2011 for clinical CROs

**) 29 countries in Europe and Australia, Canada, USA, India and

Chile

Daniel Spasic

CEO and founder of TFS

TFS commitment to Quality

Year Type of Inspection Agency Critical Major Minor

2007 Phase I Unit/TFS System MPA 0 0 8

2008 Study Site MPA 0 0 7

2009Phase I Unit/TFS System

(pre-NDA file)FDA No 483

Phase I Unit/TFS System MPA 0 0 6

2010 Study Site EMA 0 0 7

Study Site JAZMP 0 0 6

CRO/TFS System MHRA 0 0 5

2011 Study Site MHRA 0 0 6

Study Site MHRA 0 0 6

TFS Group Organisation

TFS Geographical coverage

Regional Headquarters

Country Offices

TFS Clinical Trial Engagements

Headquarters

TFS Global HQ Sweden

TFS European Regional HQ• North• West & East• South

TFS Country Offices

United Kingdom USA Germany Spain Italy France The Netherlands Belgium Sweden Norway Denmark Finland Portugal Hungary Poland Czech Republic The Baltic (Estonia, Latvia, Lithuania)

TFS European Locations

Therapeutic Areas

Therapeutic Areas in all BA

(2012)*

*) Based on 800 clinical study protocols during 2012 in all

business areas; EXPLORE, DEVELOP and PEOPLE

Oncology 32%

CNS/Neurology 6%

Cardiovascular 9%

Endocrinology 3%

Musculoskeletal 5%

Gastrointestinal 2%

Dermatology 4%

Hematology 10%

Vaccine 3%

Immunology/

Inflammation 10%

Urology 1%

Respiratory 2%

Infection 2%

Medical Device 2%

Psychiatry 1%

Pain 1%

Ophthalmology 2%

Other 5%

Client Base

Distribution of Client Segments

(2012)*

*) Based on 203 unique client companies invoiced during 2012

**) “Other” includes: Generics, Functional Food and Diagnostics

Biotech 22%

Pharma SME 20%

Big Pharma 9%

Medical Device 7%

CRO 8%

Other 21%**

Academia 13%

Revenues per Client Segment

(2012)*

*) Based on 203 unique client companies invoiced during 2012

**) “Other” includes: Generics, Diagnostics, Nutrition, CROs and

Medical Device

Big Pharma 60%

Biotech 15%

Pharma SME 15%

Other** 7%

Academia 3%

20 Largest Customers

(2012)

Why Customers Select TFS

Capacity to manage

global trials

Navigate through complex regulatory

landscape

Balanced geographical footprint throughout

European countries and USA

Mid-sized organisation hosting all

clinical development areas

Possibility to follow the development from

Phase I to Post-launch trials

High competence and therapeutic area

knowledge among the TALs

Well positioned within the CRO

business

Not too large to lose customer attention, not

too small to pose a risk

Price for services meets expectations

by customers

Experience, track-record and

reputation

Consistent proven track-record in

operational deliverables

Strong references among the leading life

science sponsors

Business Solutions

Phase 0/I and PoC trials;

~ 10 employees

Phase II – IV trials; 34 countries world-wide (2011)

~ 270 employees

Clinical research professionals within FSP models;

~ 220 employees

Specialist training for clinical research professionals;

www.tfsacademy.com

~ 5 employees

Four Dedicated Business Areas

www.tfscro.com